Abstract

New hope for a microRNA therapy for pulmonary arterial hypertension

Highlights

  • An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension by Kim, J., Kang, Y., Kojima, Y., Lighthouse, J

  • Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling and right heart failure

  • PAH demonstrates muscularization of distal pulmonary arterioles, concentric thickening, and obstruction of vascular lumen due to the proliferation of pulmonary artery endothelial cells (PAECs) and pulmonary artery smooth muscle cells (PASMCs) (Steiner et al, 2009). Such arteriopathy in PAH leads to a life threatening increase in resistance of PAECs and PASMCs to apoptosis

Read more

Summary

Introduction

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling and right heart failure. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension by Kim, J., Kang, Y., Kojima, Y., Lighthouse, J. This pathogenesis of PAH shares similarities with cancer, in which angiogenesis is characterized by an increase in proliferating endothelial cells and atypical morphology of tumor vasculature (Hoff and Machado, 2012).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call